Business Segments · Net loss
Business Segments — Net loss
Veradermics Business Segments — Net loss decreased by 119.6% to -$27.23M in Q1 2026 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalLower is better
VolatilityModerate
First reportedQ1 2025
Last reportedQ1 2026
Rolls up toNet Income
How to read this metric
A narrowing loss is generally positive, indicating improved efficiency or progress toward commercialization, while a widening loss indicates increased spending.
Detailed definition
This metric represents the net financial loss generated by the company's operations after accounting for all revenues an...
Peer comparison
Standard metric for all pre-commercial biotech companies, used to calculate the 'cash runway'.
Metric ID:
mane_segment_reportable_segment_net_lossHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | -$12.40M | -$27.23M |
| QoQ Change | — | -119.6% |
| YoY Change | — | -119.6% |
Range-$27.23M – -$12.40M
Avg YoY Growth-119.6%
Median YoY Growth-119.6%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Veradermics 's business segments — net loss?
- Veradermics (MANE) reported business segments — net loss of -$27.23M in Q1 2026.
- What does business segments — net loss mean?
- The total amount of money the company is losing on its operations during the period.